Coumaric acid

Coumaric Acid (p-Coumaric Acid): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Natural Forms

Coumaric acid is the collective name for a group of naturally occurring hydroxycinnamic acids. Coumaric acid is a hydroxy derivative of cinnamic acid with three different isomers: ortho (o-), meta (m-), and para (p-). Its most commonly available and biologically studied form is p-coumaric acid, also known as 4-hydroxycinnamic acid — a potent phenolic compound found to exist naturally in various plants, cereals, fruits, and vegetables.

p-Coumaric acid is an organic compound with the molecular formula HOC₆H₄CH=CHCO₂H. Its systematic IUPAC name is (E)-3-(4-hydroxyphenyl)prop-2-enoic acid, and it carries the CAS number 501-98-4 for the trans (E) isomer, which predominates in nature. It is a white solid that is only slightly soluble in water but very soluble in ethanol and diethyl ether. The molecular weight is 164.16 g/mol and the molecular formula is C₉H₈O₃.

It is one of the major constituent compounds of the phenolic polymer lignin in lignocellulosic materials. It is also a precursor to many natural products, especially lignols — precursors to the woody mass that comprises many plants. It is biosynthesized from cinnamic acid by the action of the P450-dependent enzyme 4-cinnamic acid hydroxylase (C4H). In prokaryotes and some plants, an alternative biosynthetic route exists: p-coumaric acid is synthesized from L-tyrosine in a reaction catalyzed by L-tyrosine ammonia lyase.

1.1 Isomeric Distinctions

• o-Coumaric acid (2-hydroxycinnamic acid) — PubChem CID 637540; upon lactonization yields coumarin (the lactone), which has a distinct pharmacological profile and should not be confused with p-coumaric acid.
• m-Coumaric acid (3-hydroxycinnamic acid) — the least abundant isomer in nature.
• p-Coumaric acid (4-hydroxycinnamic acid) — the dominant biologically active form and the principal subject of nutritional and pharmacological research.

p-Coumaric acid can be found in the free form or conjugated with other molecules; therefore, its bioavailability and the pathways via which it is metabolized change according to its chemical form. Cumulative evidence from multiple studies indicates that conjugation of p-coumaric acid greatly strengthens its biological activities; however, the high biological activity but low absorption of its conjugates remains a puzzle.

1.2 Common Forms and Preparations

p-Coumaric acid is commercially available as a pure crystalline powder (free acid form), as well as in the form of its sodium and potassium salts (p-coumarate). It appears in cosmetic formulations as an active skin-lightening ingredient. Different extraction methods have been employed to obtain it, including conventional approaches such as solvent extraction, acidification, and alkaline extraction, as well as more recent approaches such as the clip-off method, sugaring-out method, and soft microwave extraction. In foods and biological systems, it is most often found esterified to polysaccharides, organic acids (e.g., as p-coumaroyltartaric acid in wine), glycosides, and lignin. p-Coumaric acid glucoside can be found in commercial breads containing flaxseed, and diesters of p-coumaric acid can be found in carnauba wax.

2. Natural Sources and Dietary Occurrence

Para-coumaric acid (p-CA) is a plant-derived secondary metabolite belonging to the phenolic compounds. It is widely distributed in the plant kingdom and found mainly in fruits, vegetables, and cereals.

p-Coumaric acid can be found in a wide variety of edible plants and fungi such as peanuts, navy beans, tomatoes, carrots, basil, and garlic. It is found in wine and vinegar, and also in barley grain. p-Coumaric acid from pollen is a constituent of honey.

p-Coumaric acid is found in almost all food groups, including beverages (coffee, tea), fruits (berries, grapes), cereals (barley, corn, oats), and vegetables (celery, tomato). Other abundant sources include apples and berries (69–1700 mg/kg) and maize bran (2.9 g/kg).

The levels of p-coumaric and caffeic acids in blueberry fruits varies from 0.40 to 15.78 and 1.38 to 6.32 mg/g fresh weight, respectively. In red wine, it is present as a free acid (about 22 mg/L) and as p-coumaroyltartaric acid (about 139 mg/L).

p-Coumaric acid is present in a majority of fruits, but is less abundant than caffeic acid. p-Coumaric acid is also abundant in Chinese herbal medicines.

3. Traditional and Historical Use

It is important to note that p-coumaric acid as a chemically isolated compound is a modern construct. Historically and traditionally, it was not used as a purified substance but rather as part of complex multi-herb preparations in which it is one of many co-occurring phytochemicals. Its presence in these traditional medicines has only been confirmed using modern analytical chemistry.

3.1 Traditional Chinese Medicine

Bambusae Caulis in Taeniam (BC, a preparation made from bamboo) has been used as a traditional Chinese medicine for the treatment of hypertension and cardiovascular disease in China and Korea. BC has additionally been recorded to relieve fever, vomiting, stomachache, diarrhea, and chest-diaphragm inflammation in the materia medica of past dynasties in Chinese history, and has been certified as a functional food material by the Ministry of Health in China. Modern analysis confirms that p-coumaric acid is a measurable constituent of this preparation. p-CA is a common compound found in medicinal herbs including BC, and has been used to treat various diseases in China and Korea.

In China, Oldenlandia diffusa (OD) is a natural herb that is widely used and has been proven to be effective in the treatment of rheumatoid arthritis (RA). Among the herbs traditionally used in TCM prescriptions for RA, OD is a key component. Subsequent laboratory work identified p-coumaric acid as the primary plasma-absorbable compound from OD decoctions in animal models.

In traditional Chinese medicine, prescriptions consisting of multiple herbs are used to treat RA patients, with many patients experiencing marked beneficial effects. The broader framework of TCM plant medicine, in which p-coumaric acid-containing herbs feature, encompasses decoctions, powders, and formulated pill preparations.

3.2 Ayurvedic Tradition

Ayurveda is a branch of Indian science dealing with medicine, herbalism, taxology, anatomy, surgery, alchemy, and related topics. Traditional practice of Ayurveda in ancient India dates back to at least the first millennium BC. Numerous plants used in Ayurvedic practice — including preparations containing pineapple leaf, turmeric, and various grain-based foods — contain measurable quantities of p-coumaric acid, though the compound was not isolated or named in classical Ayurvedic texts. Its presence has been confirmed through modern phytochemical analysis of Ayurvedic botanicals.

3.3 Honey and Propolis in Traditional Medicine

Honey — used medicinally across many cultures for millennia — is a recognized dietary source of p-coumaric acid, which derives from pollen. Research has found that honeybees fed with honey are more pesticide-resistant than those fed with substitutes such as corn syrup, and that p-coumaric acid extracted from honey increases bees' metabolism of the miticide coumaphos. This suggests that the presence of p-coumaric acid in honey may contribute to its traditionally observed properties.

4. Key Constituents, Derivatives, and Biosynthesis

p-Coumaric acid (p-CA), a hydroxycinnamic acid-family phenolic acid, is synthesized biologically via the shikimate pathway using phenylalanine and tyrosine as precursors.

Natural and synthetic derivatives of p-coumaric acid include amides, esters, aldehydes, polymers, and copolymers. Among the biologically relevant conjugates occurring naturally in plants are:

• p-Coumaroyl esters — e.g., p-coumaroyltartaric acid (in wine) and p-coumaroylquinic acid.
• p-Coumaroyl glycosides — widely found in berries, argan fruits, and other plant sources.
• Lignin-bound p-coumarate — esterified to the cell walls of grasses and cereals.
• N-coumaroyldopamine and N-caffeoyldopamine — nitrogen-containing conjugates found in some plants.

p-Coumarate is also used as a precursor for natural aromatic organic compounds, including p-hydroxybenzoic acid and 4-vinylphenol, as well as a variety of commodity chemicals including caffeate. p-Coumaric acid is also the precursor of 4-ethylphenol produced by the yeast Brettanomyces in wine. The enzyme cinnamate decarboxylase catalyzes the conversion of p-coumaric acid into 4-vinylphenol, and vinyl phenol reductase then reduces 4-vinylphenol to 4-ethylphenol.

5. Mechanisms of Action

5.1 Antioxidant and Free Radical Scavenging

Various in vivo and in vitro studies have shown p-CA to be a powerful antioxidant, anti-diabetic, anti-cancer, and anti-inflammatory agent. Studies report that p-CA enhances the production of antioxidant enzymes by activating the ARF/Nrf-2 pathway. The phenolic hydroxyl group on the para position of the benzene ring is structurally responsible for its electron-donating and hydrogen atom-donating capacity, which underlies its free radical scavenging activity.

Due to its potent free radical scavenging activity, it can mitigate the ill effects of various diseases including arthritis, neurological disorders, and cardiovascular diseases.

5.2 Anti-inflammatory Mechanisms

In a lipopolysaccharide (LPS)-induced sepsis rat model, p-CA showed antioxidant and anti-inflammatory effects in vivo. At 100 mg/kg body weight, it reduced the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in lungs and liver, and further increased the levels of anti-inflammatory cytokines (IL-4, IL-10) when treated in combination with ellagic acid.

In both chronic kidney disease rats and LPS-induced C2C12 myoblasts, p-CA exhibited anti-inflammatory and antioxidant effects, reduced the levels of pro-inflammatory cytokines, and enhanced the activity of antioxidant enzymes.

5.3 Antimelanogenic and Tyrosinase Inhibition

p-Coumaric acid has the optimal structure to be a competitive inhibitor of tyrosinase that catalyzes key reactions in the melanin biosynthetic pathway. Experimental evidence supports this notion — it was found to be a more potent inhibitor of tyrosinase, especially toward human enzymes, than other well-known tyrosinase inhibitors such as arbutin and kojic acid. p-Coumaric acid inhibited melanin synthesis in murine melanoma cells, human epidermal melanocytes, and reconstituted three-dimensional human skin models.

p-Coumaric acid has a chemical structure similar to L-tyrosine and inhibits the activity of tyrosinase, which catalyzes the oxidation of L-tyrosine and/or L-DOPA to L-DOPA quinone in the melanin biosynthetic pathway. Due to its UV absorption and antioxidant action, p-coumaric acid can inhibit the signaling pathways linked to gene expression of tyrosinase and inflammatory mediators. p-Coumaric acid can also reduce the stimulatory effects of hormones and L-tyrosine on the gene expression of tyrosinase.

5.4 Antiplatelet Activity

In vitro and in vivo research has shown that p-coumaric acid inhibits platelet aggregation. A peer-reviewed study published in the British Journal of Nutrition found that administered in vivo, p-coumaric acid was able to significantly reduce platelet aggregation induced by arachidonic acid (AA) and ADP after 2 weeks of treatment at a dose comparable to the daily intake for cinnamates. TXB₂ production measurements were well correlated with platelet aggregation in both experiments.

5.5 GABAergic Anxiolytic Mechanisms

p-Coumaric acid is a naturally occurring phenolic compound known for its antioxidant, anti-inflammatory, and antimicrobial properties. An in vivo and in silico study used behavioral tests and molecular docking with GABA-A receptor subunits to examine its anxiolytic effect and assess its underlying mechanism. A study referenced in a 2016 review in the Journal of the Science of Food and Agriculture noted that p-coumaric acid activates the GABA-A receptor in vitro and is orally anxiolytic in vivo (Scheepens et al., Phytotherapy Research, 2014).

5.6 Nrf2 Pathway Activation and Hepatoprotection

One study evaluated pretreatment with p-CA against heart dysfunction, oxidative stress, and nuclear factor-erythroid 2-related factor 2 (Nrf2) modifications following lipopolysaccharide (LPS)-induced acute lung inflammation. Nrf2 is a master transcription factor that coordinates the cellular antioxidant defense response, and its activation by p-coumaric acid represents a key mechanistic pathway for multiple downstream organ-protective effects.

6. Scientific Evidence by Area of Use

6.1 Antioxidant and Oxidative Stress

Evidence level: Moderate; predominantly preclinical (in vitro and animal) with limited human data.

Various in vivo and in vitro studies have revealed p-CA's scavenging and antioxidative properties in the reduction of oxidative stress and inflammatory reactions. p-Coumaric acid acts as a potent systemic antioxidant and shows good antiaggregant properties at concentrations that can be obtained through regular consumption of vegetables, cereals, fruits, or a moderate quantity of red wine. No large-scale randomized controlled trials in humans have been conducted specifically for p-coumaric acid as an isolated antioxidant supplement.

6.2 Anti-Inflammatory Activity

Evidence level: Preliminary; animal and cell-based studies only.

p-Coumaric acid was identified as the absorbed compound in plasma in a study using collagen-induced arthritis (CIA) model rats. After administration of p-CA solution or the OD decoction, symptoms in the treated rats were alleviated compared to the untreated model rats, and inflammatory cell infiltration was suppressed.

In rats at a dose of 100 mg/kg body weight, p-CA reduced the effects of monosodium urate (MSU) crystals by its anti-inflammatory activity in vivo. MSU triggers inflammatory reactions by enhancing the release of cytokines that result in gout. p-CA, by virtue of its antioxidant and anti-inflammatory activities, reduced the expression of these cytokines. All of these studies are animal-based; human clinical trials are lacking.

6.3 Cardiovascular Health

Evidence level: Preliminary; animal studies and limited human antiplatelet study.

The most directly relevant human-applicable evidence concerns antiplatelet activity. A study published in the British Journal of Nutrition (Luceri et al., 2007) showed that administered in vivo, p-coumaric acid was able to significantly reduce platelet aggregation induced by AA and ADP after 2 weeks of treatment at a dose comparable to the daily dietary intake for cinnamates.

In a separate preclinical study, rats were divided into groups including a p-CA group (100 mg/kg, IP) and an LPS+p-CA group. Inflammatory response and oxidative stress were evaluated by measurement of IL-6, TNF-α, and MDA levels in heart tissue, and the results showed anti-inflammatory and antioxidative effects of p-CA on LPS-induced acute lung injury.

A p-coumaric acid conjugate study (4-ACGC) found that treatment significantly reduced cardiac hypertrophy and reversed ejection fraction, heart rate, fractional shortening, and cardiac output changes in chronic heart failure (CHF) rats, and the treatment could effectively inhibit inflammatory cytokines induced by CHF. No equivalent human trials exist.

6.4 Anti-Diabetic and Metabolic Effects

Evidence level: Preliminary; in vitro and animal studies only.

p-CA showed anti-inflammatory, antioxidant, anticancer, hepatoprotective, neuroprotective, and hypoglycemic potential. One study revealed that p-CA increased plasma insulin levels, adjusted glucose levels, and improved antioxidant conditions in rats with streptozotocin-induced diabetes. Biological activities documented for p-coumaric acid and its conjugates include mitigatory effects against diabetes, obesity, hyperlipaemia, and gout. No human clinical trials specifically assessing p-coumaric acid as an anti-diabetic intervention have been published.

6.5 Anticancer Properties

Evidence level: Preliminary; in vitro and animal only. No human trial evidence.

p-Coumaric acid (p-CouA), a phenolic compound and cinnamic acid derivative found in several fruits, vegetables, and herbs, has a growing body of evidence suggesting it may be an effective agent for preventing and managing colorectal cancer. Molecular mechanisms underlying its anticancer effects include anti-inflammatory and antioxidant potentials, apoptosis induction, and cell cycle blockade, as well as an impact on clonogenicity and multidrug resistance of colorectal cancer cells.

A cell-based study referenced in one review found that after 2–3 days of treatment, the acid was effective at 1500 μM and had the potential to reduce the number of cells up to 43–75% of control in colon tumor cell lines. The acid was also found to be effective on Caco-2 human cancer cells. These concentrations, however, are far in excess of physiologically achievable dietary levels, and all evidence is in vitro. Human trials have not been conducted.

6.6 Dermatology: Antimelanogenic and UV-Protective Effects

Evidence level: Moderate; cell and animal studies well-developed, with limited but supportive human data.

Topical application of p-coumaric acid onto the dorsal skin of hairless mice attenuated the inflammatory erythema responses caused by UV. Pre-application of p-coumaric acid on human skin attenuated erythema due to UV exposure.

Ex vivo skin permeation experiments and in vivo efficacy tests for p-coumaric acid confirmed its efficient transdermal delivery and functional efficacy in reducing erythema development and skin pigmentation due to ultraviolet radiation exposure. Human studies further supported its effectiveness in hypopigmentation and depigmentation.

The clinical outcome from human studies was supportive for the efficacy of p-coumaric acid in attenuating UV-induced inflammation and subsequent pigmentation. The antimelanogenic effects in UV-exposed skin are considered to involve multiple mechanisms: (1) absorption of UV, (2) inhibition of new synthesis of tyrosinase, and (3) inhibition of catalytic activity of preexisting tyrosinase.

Because p-coumaric acid is an amphiphilic compound that possesses both hydrophobic and hydrophilic properties at neutral pH, its transdermal delivery can be faster than methyl p-coumarate, which is very hydrophobic. Future studies are needed to extensively examine its safety and efficacy and to develop an optimized cosmetic formulation for the best performance in skin lightening.

6.7 Neuroprotective Effects

Evidence level: Preliminary; animal studies only.

In a mouse model of cerebral ischemia-reperfusion injury, IR caused significant increases in calcium and malondialdehyde (MDA) levels, whole brain infarction volume, and hippocampal neuronal death. Pretreatment with p-coumaric acid significantly reduced MDA levels, whole-brain infarction volume, and hippocampal neuronal death, and increased catalase and superoxide dismutase activities.

Results from a rat model of embolic cerebral ischemia showed that p-coumaric acid is a neuroprotective agent on account of its strong antioxidant and anti-apoptotic features, and that p-coumaric acid decreased focal ischemia. The authors called for extra effort to introduce p-coumaric acid as a promising therapeutic agent for treatment of human cerebral ischemia in the future. No human neurological trials have been published.

6.8 Anxiolytic Effects

Evidence level: Preliminary; one animal study with in silico molecular docking.

One study used behavioral tests and in silico molecular docking with GABA-A receptor subunits to examine the anxiolytic effect of p-CA. p-CA was administered orally at dosages of 25 mg/kg and 50 mg/kg in Swiss albino mice, with the GABAergic agonist diazepam (1 mg/kg) and the antagonist flumazenil (0.1 mg/kg) as controls. A variety of behavioral techniques including open field, swing box, hole cross, and dark–light tests were employed. This area is preliminary and no human data exists.

6.9 Renoprotection

Evidence level: Preliminary; animal studies only.

In a study using 5/6 nephrectomized rats as a CKD model, PCA ameliorated kidney injury in CKD rats and increased skeletal muscle weight and the cross-sectional area of muscle fibers. Separate research cited in peer-reviewed literature noted that p-coumaric acid protects cadmium chloride-induced nephrotoxicity in rats (Navaneethan & Rasool, Renal Failure, 2014). No human studies have been reported.

6.10 Hepatoprotective Effects

Evidence level: Preliminary; animal studies only.

p-CA alleviated pathological changes caused by dust exposure and ischemia-reperfusion (IR) injury in liver tissue. p-CA protected hepatic injury induced by dust and IR by inhibition of oxidative injury, inflammation, and autophagy. No human hepatoprotection trials have been conducted.

7. Bioavailability and Pharmacokinetics

Limited studies suggest that the relative bioavailability of hydroxycinnamates may follow the order: chlorogenic acid < rosmarinic acid < caffeic acid < ferulic acid < p-coumaric acid. This places p-coumaric acid as the most bioavailable among its hydroxycinnamic acid counterparts.

Ferulic acid and p-coumaric acid are absorbed by the monocarboxylic acid transporter (MCT) in Caco-2 cells, whereas gallic acid is not. Therefore, the MCT is selective for certain phenolic acids. Ingested p-coumaric acid was rapidly absorbed in the gastrointestinal tract in an intact form. The serum concentration of intact p-coumaric acid in the portal vein peaked 10 minutes after dosing (Cmax was 165.7 µmol/L) in rats administered 100 µmol/kg body weight.

While p-coumaric acid in free form is easily and quickly absorbed in the upper gastrointestinal tract, its conjugates exhibit much fewer and slower absorption, with a higher proportion reaching the colon. The bioavailability of p-CA is influenced by its chemical form and the food matrix, with the gut microbiota playing a key role in its metabolism.

In a human pharmacokinetic study, an analysis method using p-CA present in Bambusae Caulis in Taeniam (BC) extract was developed using UPLC-MS/MS. The study found that p-CA can serve as an indicator substance in high amounts in BC extract, and that important pharmacokinetic parameters such as Tmax, Cmax, T½, and AUCt were well-detected in human subjects.

Despite its promising biological activities, p-coumaric acid suffers from poor aqueous solubility and limited bioavailability when presented in certain formulations, which represents a challenge for pharmaceutical development.

8. Body Systems and Health Areas Associated With p-Coumaric Acid

p-Coumaric acid and its derivatives have been found to possess different bioactive properties including antioxidant, antimicrobial, anticancer, antiarthritic, anti-inflammatory, gout prevention, anti-diabetic, anti-melanogenic, skin regeneration, gastroprotective, anti-ulcer, cardioprotective, hepatoprotective, reno-protective, bone formation, anti-angiogenic, and anti-platelet properties.

• Cardiovascular system: Antiplatelet aggregation, antioxidant protection of endothelium, reduction of cardiac inflammatory markers.
• Integumentary system (skin): Tyrosinase inhibition, UV-induced erythema reduction, antimelanogenic action, skin lightening in cosmetic applications.
• Nervous system: Neuroprotection against ischemia-reperfusion injury, anxiolytic effects mediated via GABA-A receptor interaction.
• Musculoskeletal system: Anti-arthritic effects, gout prevention (via MSU crystal-induced inflammation suppression), potential bone formation promotion.
• Liver (hepatic system): Protection against oxidative injury, dust-induced and ischemia-reperfusion hepatopathy.
• Kidney (renal system): Protection against nephrotoxic agents and CKD-associated muscle atrophy.
• Metabolic and endocrine: Antidiabetic and antihyperlipidemic effects in animal models.
• Immune and inflammatory: Downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); upregulation of anti-inflammatory cytokines (IL-4, IL-10).
• Gastrointestinal: Gastroprotective and antiulcer effects reported in animal models.

9. Dosage Forms and Doses Reported in Studies

There is currently no established recommended daily intake or standardized therapeutic dose for p-coumaric acid as an isolated supplement in humans. The following are doses reported in published research:

• In a rat study of LPS-induced acute lung injury and cardiac function, p-CA was administered at 100 mg/kg body weight (IP).
• In a gout model, p-CA was administered at 100 mg/kg body weight in rats.
• In a mouse anxiolytic study, p-CA was administered orally at dosages of 25 mg/kg and 50 mg/kg.
• The estimated daily dietary intake for total cinnamates and hydroxybenzoic acid derivatives is approximately 1 g/day, corresponding to about 15 mg/kg per day in humans.
• In a study showing in vivo platelet aggregation inhibition, the dose used was comparable to the daily dietary intake for cinnamates, over 2 weeks of treatment.
• In the human PK/PD study involving Bambusae Caulis in Taeniam extract in children, the sample comprised 34 subjects (placebo = 18, treatment = 16). The specific isolate dose of p-CA in this study was not separately reported from the whole botanical extract.
• In cosmetic applications, a cream containing 1.5% p-coumaric acid was evaluated in experimental skin pigmentation studies.

10. Safety Considerations and Interactions

10.1 Acute Toxicity

p-Coumaric acid (4-hydroxycinnamic acid) is a phenolic acid that has low toxicity in mice, with an LD50 of 2850 mg/kg body weight. It serves as a precursor of other phenolic compounds and exists either in free or conjugated form in plants. This low acute toxicity profile is consistent with its widespread presence in the human diet.

10.2 Dietary Safety and General Exposure

p-Coumaric acid is consumed daily as an ordinary component of fruit-, vegetable-, and cereal-based diets. It shows good antiaggregant properties at concentrations that can be obtained through regular consumption of vegetables, cereals, fruits, or a moderate quantity of red wine. No formal tolerable upper intake level has been established by regulatory bodies such as EFSA or the NIH Office of Dietary Supplements for p-coumaric acid as a supplement.

10.3 Antiplatelet Interaction Concern

In vitro and in vivo research has shown that p-coumaric acid inhibits platelet aggregation. This property, while potentially cardioprotective, represents a theoretical interaction risk in individuals taking anticoagulant or antiplatelet medications (e.g., warfarin, aspirin, clopidogrel). No human drug-interaction studies have formally investigated this to date.

10.4 Distinction from Coumarin (Anticoagulant)

A critical safety distinction must be made: p-coumaric acid is not the same as coumarin (2H-chromen-2-one), which is a lactone formed by the cyclization of o-coumaric acid. The vitamin K epoxide reductase (VKORC1), the key enzyme of the vitamin K cycle, is the molecular target of coumarins (such as warfarin), but this anticoagulant mechanism does not apply to p-coumaric acid. The two compounds are structurally and pharmacologically distinct.

10.5 Bioavailability-Related Considerations

The chemical structures, existing forms, and/or doses of hydroxycinnamates may affect their metabolic fate. Cumulative evidence from multiple studies indicates that conjugation of p-coumaric acid greatly strengthens its biological activities; however, the high biological activity but low absorption of its conjugates remains a puzzle. Formulation-dependent bioavailability variability is therefore a significant consideration when interpreting supplemental vs. dietary exposure.

10.6 Evidence Gaps

As of the current evidence base, the overwhelming majority of mechanistic and efficacy data for p-coumaric acid is derived from in vitro cell studies and in vivo animal models. Significant knowledge gaps remain, including limited clinical evidence, unclear optimal dosages, low bioavailability in certain forms, and an incomplete understanding of molecular mechanisms. Further pharmacokinetic and pharmacodynamic studies are required to characterize the metabolism of hydroxycinnamates and their potential health impact in humans.

References

• PubChem: p-Coumaric Acid (CID 637542) — NIH/NLM
• Scavenging Properties of Plant-Derived Natural Biomolecule Para-Coumaric Acid in the Prevention of Oxidative Stress-Induced Diseases — PMC (2021)
• p-Coumaric Acid as an Active Ingredient in Cosmetics: A Review Focusing on its Antimelanogenic Effects — PMC / Antioxidants (2019)
• New Insights Into the Anticancer Effects of p-Coumaric Acid: Focus on Colorectal Cancer — PMC (2023)
• Anti-Inflammatory Effects of p-Coumaric Acid, a Natural Compound of Oldenlandia diffusa, on Arthritis Model Rats — PMC (2018)
• p-Coumaric Acid Protects Cardiac Function Against LPS-Induced Acute Lung Injury by Attenuation of Oxidative Stress — PMC (2019)
• The Cardioprotective Effects of 4-ACGC (p-coumaric acid conjugate) on Chronic Heart Failure — PMC (2018)
• Development of p-Coumaric Acid Analysis in Human Plasma and Its Clinical Application to PK/PD Study — PMC / Journal of Clinical Medicine (2021)
• Neuroprotective Effect of p-Coumaric Acid in Rat Model of Embolic Cerebral Ischemia — PMC (2015)
• p-Coumaric Acid Has Pure Anti-Inflammatory Characteristics Against Hepatopathy Caused by Ischemia-Reperfusion in the Liver and Dust Exposure — PMC (2023)
• P-Coumaric Acid Improves Skeletal Muscle Atrophy in Chronic Kidney Disease — PMC (2025)
• Pei K. et al., p-Coumaric Acid and Its Conjugates: Dietary Sources, Pharmacokinetic Properties and Biological Activities — Journal of the Science of Food and Agriculture (2016)
• Luceri C. et al., p-Coumaric Acid, a Common Dietary Phenol, Inhibits Platelet Activity In Vitro and In Vivo — British Journal of Nutrition (2007)
• Konishi Y. et al., Intestinal Absorption of p-Coumaric and Gallic Acids in Rats after Oral Administration — Journal of Agricultural and Food Chemistry (2004)
• Neuroprotective Effect of p-Coumaric Acid in Mice with Cerebral Ischemia Reperfusion Injuries — Metabolic Brain Disease (2018)
• p-Coumaric Acid: A Naturally Occurring Chemical with Potential Therapeutic Applications — Current Organic Chemistry, Bentham Science (2022)
• Bioactivity and Toxicity of Coumarins from African Medicinal Plants — PMC (2024)
• Natural Sources, Pharmacokinetics, Biological Activities and Health Benefits of Hydroxycinnamic Acids and Their Metabolites — PMC (2020)
• Anxiolytic-like Effects of p-Coumaric Acid via GABAergic Interaction Pathways — Naunyn-Schmiedeberg's Archives of Pharmacology (2026)
• p-Coumaric Acid — Wikipedia (as a structural/botanical reference cross-check)